Infliximab biosimilar gets PBS listing


From the 1st December the infliximab biosimilar Inflectra™ will be listed on the PBS for the same indications that apply to its comparator drug Remicade™. The PBS update shows that Inflectra™ and its originator biologic is marked as equivalent on the Schedule of Pharmaceutical Benefits (‘a’ flagged), for the purposes of substitution by a pharmacist ...


Already a member? Login to keep reading


OR
© 2017 the limbic